These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 35812443)
81. Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression. Zhang J; Ding X; Peng K; Jia Z; Yang J Aging (Albany NY); 2022 Jun; 14(11):4839-4857. PubMed ID: 35680563 [TBL] [Abstract][Full Text] [Related]
82. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer. Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L Front Immunol; 2022; 13():974034. PubMed ID: 36203594 [TBL] [Abstract][Full Text] [Related]
84. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer. Zhang P; An Z; Sun C; Xu Y; Zhang Z Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210 [TBL] [Abstract][Full Text] [Related]
85. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment. Jiang Z; Liu Z; Li M; Chen C; Wang X EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888 [TBL] [Abstract][Full Text] [Related]
86. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment. Gao B; Wang Y; Lu S Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232 [TBL] [Abstract][Full Text] [Related]
87. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis. Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566 [TBL] [Abstract][Full Text] [Related]
88. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma. Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712 [TBL] [Abstract][Full Text] [Related]
89. Characterization of metabolism-associated molecular patterns in prostate cancer. Yang B; Jiang Y; Yang J; Zhou W; Yang T; Zhang R; Xu J; Guo H BMC Urol; 2023 Jun; 23(1):104. PubMed ID: 37280589 [TBL] [Abstract][Full Text] [Related]
90. Targeting adenosine and regulatory T cells in cancer immunotherapy. Churov A; Zhulai G Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376 [TBL] [Abstract][Full Text] [Related]
91. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer. Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432 [TBL] [Abstract][Full Text] [Related]
92. T-cell immunoglobulin and ITIM domain in cancer immunotherapy: A focus on tumor-infiltrating regulatory T cells. Tian X; Ning Q; Yu J; Tang S Mol Immunol; 2022 Jul; 147():62-70. PubMed ID: 35504059 [TBL] [Abstract][Full Text] [Related]
93. Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients. Xiao Z; Nie K; Han T; Cheng L; Zhang Z; Peng W; Shi D J Immunol Res; 2021; 2021():6439975. PubMed ID: 34541005 [TBL] [Abstract][Full Text] [Related]
94. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Flammiger A; Weisbach L; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M Eur J Cancer; 2013 Apr; 49(6):1273-9. PubMed ID: 23266046 [TBL] [Abstract][Full Text] [Related]
95. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L Front Immunol; 2022; 13():943389. PubMed ID: 36003381 [TBL] [Abstract][Full Text] [Related]
96. Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy. Hong K; Cen K; Chen Q; Dai Y; Mai Y; Guo Y Front Immunol; 2023; 14():1128390. PubMed ID: 36761753 [TBL] [Abstract][Full Text] [Related]
97. Regulatory T cells subgroups in the tumor microenvironment cannot be overlooked: Their involvement in prognosis and treatment strategy in melanoma. Huang W; Kim BS; Zhang Y; Lin L; Chai G; Zhao Z Environ Toxicol; 2024 Oct; 39(10):4512-4530. PubMed ID: 38530049 [TBL] [Abstract][Full Text] [Related]
98. Targeting tumor-infiltrating tregs for improved antitumor responses. Qin D; Zhang Y; Shu P; Lei Y; Li X; Wang Y Front Immunol; 2024; 15():1325946. PubMed ID: 38500876 [TBL] [Abstract][Full Text] [Related]
99. Differentiation, regulation and function of regulatory T cells in non-lymphoid tissues and tumors. Ni H; Chen Y Int Immunopharmacol; 2023 Aug; 121():110429. PubMed ID: 37327512 [TBL] [Abstract][Full Text] [Related]
100. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. Li Y; Zhang C; Jiang A; Lin A; Liu Z; Cheng X; Wang W; Cheng Q; Zhang J; Wei T; Luo P J Transl Med; 2024 Mar; 22(1):293. PubMed ID: 38509593 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]